Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 34508 [E5-3062]

Download as PDF 34508 Federal Register / Vol. 70, No. 113 / Tuesday, June 14, 2005 / Notices If a hearing is requested, the Commission will make a final determination on the issue of no significant hazards consideration. The final determination will serve to decide when the hearing is held. If the final determination is that the amendment request involves no significant hazards consideration, the Commission may issue the amendment and make it immediately effective, notwithstanding the request for a hearing. Any hearing held would take place after issuance of the amendment. If the final determination is that the amendment request involves a significant hazards consideration, any hearing held would take place before the issuance of any amendment. Nontimely requests and/or petitions and contentions will not be entertained absent a determination by the Commission or the presiding officer of the Atomic Safety and Licensing Board that the petition, request and/or the contentions should be granted based on a balancing of the factors specified in 10 CFR 2.309(c)(1)(i)–(viii). A request for a hearing or a petition for leave to intervene must be filed by: (1) First class mail addressed to the Office of the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 0001, Attention: Rulemaking and Adjudications Staff; (2) courier, express mail, and expedited delivery services: Office of the Secretary, Sixteenth Floor, One White Flint North, 11555 Rockville Pike, Rockville, Maryland, 20852, Attention: Rulemaking and Adjudications Staff; (3) E-mail addressed to the Office of the Secretary, U.S. Nuclear Regulatory Commission, HEARINGDOCKET@NRC.GOV; or (4) facsimile transmission addressed to the Office of the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC, Attention: Rulemakings and Adjudications Staff at (301) 415–1101, verification number is (301) 415–1966. A copy of the request for hearing and petition for leave to intervene should also be sent to the Office of the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 0001, and it is requested that copies be transmitted either by means of facsimile transmission to 301–415–3725 or by email to OGCMailCenter@nrc.gov. A copy of the request for hearing and petition for leave to intervene should also be sent to Nicolas S. Reynolds, Esquire, Winston and Strawn, 1400 L Street, NW., Washington, DC 2005–3502, attorney for the licensee. For further details with respect to this action, see the application for amendment dated May 27, 2005, which VerDate jul<14>2003 20:14 Jun 13, 2005 Jkt 205001 is available for public inspection at the Commission’s PDR, located at One White Flint North, Public File Area O1 F21, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible electronically from the ADAMS Public Electronic Reading Room on the Internet at the NRC Web site http://www.nrc.gov/ reading-rm.html. Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS, should contact the NRC PDR Reference staff by telephone at 1–800–397–4209, 301– 415–4737, or by e-mail to pdr@nrc.gov. Dated at Rockville, Maryland, this 7th day of June 2005. For the Nuclear Regulatory Commission. Mel B. Fields, Senior Project Manager, Section 2, Project Directorate IV, Division of Licensing Project Management, Office of Nuclear Reactor Regulation. [FR Doc. E5–3065 Filed 6–13–05; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION Advisory Committee on the Medical Uses of Isotopes: Meeting Notice Nuclear Regulatory Commission. ACTION: Notice of meeting. AGENCY: SUMMARY: The U.S. Nuclear Regulatory Commission will convene a teleconference meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on June 28, 2005. The topic of discussion will be ‘‘Update to Medical Event Criteria Definition.’’ During this discussion, an ACMUI subcommittee will forward to the full ACMUI its recommendation(s) regarding revision of the medical event criteria definition in 10 CFR part 35, ‘‘Medical Use of Byproduct Material,’’ as this definition applies to medical events involving permanent implant brachytherapy. NRC staff is seeking the ACMUI’s recommendations on this issue, as well as any recommendations on communicating associated risks to the public. DATES: The teleconference meeting will be held on Tuesday, June 28, 2005, from 1 p.m. to 3 p.m, eastern daylight time. Public Participation: Any member of the public who wishes to participate in the teleconference discussion may contact Angela R. McIntosh using the contact information below. FOR FURTHER INFORMATION CONTACT: Angela R. McIntosh, telephone (301) 415–5030; e-mail arm@nrc.gov of the PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555– 0001. Conduct of the Meeting Leon S. Malmud, M.D., will chair the meeting. Dr. Malmud will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting: 1. Persons who wish to provide a written statement should submit a reproducible copy to Angela McIntosh, U.S. Nuclear Regulatory Commission, Two White Flint North, Mail Stop T8F5, Washington, DC 20555–0001. Hard copy submittals must be postmarked by June 20. Electronic submittals must be submitted by June 24, 2005. Any submittal must pertain to the topic on the agenda for the meeting. 2. Questions from members of the public will be permitted during the meeting, at the discretion of the Chairman. 3. The transcript and written comments will be available for inspection on NRC’s web site (http:// www.nrc.gov) and at the NRC Public Document Room, 11555 Rockville Pike, Rockville, MD 20852–2738, telephone (800) 397–4209, on or about March 18, 2005. Minutes of the meeting will be available on or about July 12, 2005. This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission’s regulations in Title 10, U.S. Code of Federal Regulations, part 7. Dated: June 8, 2005. Andrew L. Bates, Advisory Committee Management Officer. [FR Doc. E5–3062 Filed 6–13–05; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION Sunshine Act Meeting Agency Holding the Meetings: Nuclear Regulatory Commission. DATE: Weeks of June 13, 20, 27, July 4, 11, 18, 2005. PLACE: Commissioners’ Conference Room, 11555 Rockville Pike, Rockville, Maryland. STATUS: Public and Closed. MATTERS TOO BE CONSIDERED: AGENCY: Week of June 13, 2005 There are no meetings scheduled for the Week of June 13, 2005. E:\FR\FM\14JNN1.SGM 14JNN1

Agencies

[Federal Register Volume 70, Number 113 (Tuesday, June 14, 2005)]
[Notices]
[Page 34508]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-3062]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Meeting 
Notice

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission will convene a 
teleconference meeting of the Advisory Committee on the Medical Uses of 
Isotopes (ACMUI) on June 28, 2005. The topic of discussion will be 
``Update to Medical Event Criteria Definition.'' During this 
discussion, an ACMUI subcommittee will forward to the full ACMUI its 
recommendation(s) regarding revision of the medical event criteria 
definition in 10 CFR part 35, ``Medical Use of Byproduct Material,'' as 
this definition applies to medical events involving permanent implant 
brachytherapy. NRC staff is seeking the ACMUI's recommendations on this 
issue, as well as any recommendations on communicating associated risks 
to the public.

DATES: The teleconference meeting will be held on Tuesday, June 28, 
2005, from 1 p.m. to 3 p.m, eastern daylight time.
    Public Participation: Any member of the public who wishes to 
participate in the teleconference discussion may contact Angela R. 
McIntosh using the contact information below.

FOR FURTHER INFORMATION CONTACT: Angela R. McIntosh, telephone (301) 
415-5030; e-mail arm@nrc.gov of the Office of Nuclear Material Safety 
and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 
20555-0001.

Conduct of the Meeting

    Leon S. Malmud, M.D., will chair the meeting. Dr. Malmud will 
conduct the meeting in a manner that will facilitate the orderly 
conduct of business. The following procedures apply to public 
participation in the meeting:
    1. Persons who wish to provide a written statement should submit a 
reproducible copy to Angela McIntosh, U.S. Nuclear Regulatory 
Commission, Two White Flint North, Mail Stop T8F5, Washington, DC 
20555-0001. Hard copy submittals must be postmarked by June 20. 
Electronic submittals must be submitted by June 24, 2005. Any submittal 
must pertain to the topic on the agenda for the meeting.
    2. Questions from members of the public will be permitted during 
the meeting, at the discretion of the Chairman.
    3. The transcript and written comments will be available for 
inspection on NRC's web site (http://www.nrc.gov) and at the NRC Public 
Document Room, 11555 Rockville Pike, Rockville, MD 20852-2738, 
telephone (800) 397-4209, on or about March 18, 2005. Minutes of the 
meeting will be available on or about July 12, 2005.
    This meeting will be held in accordance with the Atomic Energy Act 
of 1954, as amended (primarily Section 161a); the Federal Advisory 
Committee Act (5 U.S.C. App); and the Commission's regulations in Title 
10, U.S. Code of Federal Regulations, part 7.

    Dated: June 8, 2005.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. E5-3062 Filed 6-13-05; 8:45 am]
BILLING CODE 7590-01-P